Controversies in the role of radiotherapy in the treatment of pediatric hodgkin lymphoma

Indian Journal of Pediatrics

Volumn 80, Issue 10, 2013, Pages 863-869

  Henry, Meret ^a   Savaşan, Süreyya ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Hodgkinlymphoma .Radiationtherapy .Pediatric

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BLEOMYCIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RISK; CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL TRIAL (TOPIC); HODGKIN DISEASE; HUMAN; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; RADIATION RESPONSE; RADIOTHERAPY EQUIPMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS;

EID: 84892669436     PISSN: 00195456     EISSN: 09737693     Source Type: Journal    
DOI: 10.1007/s12098-013-1106-8     Document Type: Article

References (25)

1. Barbaro PM, Johnston K, Dalla-Pozza L, Cohn RJ, Wang YA, Marshall GM, et al. Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy. Ann Oncol. 2011;22:2569-74.
2. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010;28:1232-9.
3. Omer B, Kadan-Lottick NS, Roberts KB, Wang R, Demsky C, Kupfer GM, et al. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br J Haematol. 2012;158:615-25.
4. Schellong G, Riepenhausen M, Bruch C, Kotthoff S, Vogt J, Bölling T, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55:1145-52.
5. Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study. Blood. 2011;117:1806-16.
6. Bhatti P, Veiga LH, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: An update from the childhood cancer survivor study. Radiat Res. 2010;174:741-52.
7. Demirkaya M, Sevinir B, Saǧlam H, Özkan L, Akaci O. Thyroid functions in long-term survivors of pediatric Hodgkin's lymphoma treated with chemotherapy and radiotherapy. J Clin Res Pediatr Endocrinol. 2011;3:89-94.
8. Schellong G, Pötter R, Brämswig J, Wagner W, Prott FJ, Dörffel W, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DALHD-The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol. 1999;17:3736-44.
9. Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr. 2003;215:139-45.
10. Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: The GPOH-HD-2002 study. J Clin Oncol. 2010;28:3680-6.
11. Kung FH, Schwartz CL, Ferree CR, LondonWB, Ternberg JL, Behm FG, et al. POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: A report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2006;28:362-8.
12. Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2012;59:1259-65.
13. Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J, et al. Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma-A report from the Children's Oncology Group. J Clin Oncol. 2012;30:3174-80.
14. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, et al. Randomized comparison of low-dose involvedfield radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765-71.
15. Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012;307:2609-16.
16. Friedman DL, Wolden SL, Constine L, Chen L, McCarten K, Fitzgerald TJ, et al. AHOD0031: A phase III study of doseintensive therapy for intermediate risk Hodgkin lymphoma: A report from the Children's Oncology Group. Orlando: American Society of Hematology; 2010.
17. Weiner MA, Leventhal B, BrecherML, Marcus RB, Cantor A, Gieser PW, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol. 1997;15:2769-79.
18. Kelly KM, Hutchinson RJ, Sposto R, Weiner MA, Lones MA, Perkins SL, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: Preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol. 2002;13:S107-11.
19. Kelly KM, Sposto R, Hutchinson R, Massey V, McCarten K, Perkins S, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: A report from the Children's Oncology Group. Blood. 2011;117:2596-603.
20. Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediateand high-risk Hodgkin lymphoma: The results of P9425. Blood. 2009;114:2051-9.
21. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791-9.
22. Appel BE, Chen L, Buxton A, Wolden SL, Hodgson DC, Nachman JB. Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2012;59:1284-9.
23. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumorassociated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875-85.
24. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial. Blood. 2012;120:3280-7.
25. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica. 2011;96:269-76.